000			02919cam a2200325 a 4500
003			EG-GiCUC
008			171209s2017 ua d f m 000 0 eng d
040			_aEG-GiCUC _beng _cEG-GiCUC
041	0		_aeng
049			_aDeposite
097			_aPh.D
099			_aCai01.11.33.Ph.D.2017.Ta.S
100	0		_aTarek Ahmed Moneer Abdelkhalek Ismail
245	1	0	_aSerum levels of cytokeratin 19 as a prognostic marker in patients with hepatocellular carcinoma on top of chronic HCV / _cTarek Ahmed Moneer Abdelkhalek ; Supervised Maissa Elsaid Elraziky , Sahar Abdelaty Sharaf , Hanan Abdelhafez Hamed
246	1	5	_aالمستوى المصلى للسيتوكيراتين ١٩ معامل تنبؤى لتطور المرض فى المرضى الذين يعانون من سرطان الكبد الأولى الناتج عن الالتهاب الكبدي المزمن الفيروسى سى
260			_aCairo : _bTarek Ahmed Moneer Abdelkhalek Ismail , _c2017
300			_a140 P. : _bcharts ; _c25cm
502			_aThesis (Ph.D.) - Cairo University - Faculty of Medicine - Department of Tropical Medicine
520			_aBackground: HCC is the sixth most common cancer worldwide and the third most common cause of cancer death. HCC constitutes 70.48% of all liver tumors among Egyptians. HCC represents the main complication of cirrhosis. The cytokeratin 19 (CK19) belongs to a family of keratins, which are normally expressed in the lining of the gastro- enteropancreatic and hepatobiliary tracts. CK19 immunohistochemistry has been used successfully in thyroid tumors to recognize papillary carcinomas for some time. However, its use in the pancreas, liver, and gastrointestinal tract has only recently come to the fore. Aim: To evaluate the role of the serum level of CK19 in HCC patients as a prognostic marker. Methods: We measured the serum levels of (cytokeratin 19) in hepatocellular carcinoma patients who underwent appropriate therapeutic interventions for its hepatic focal lesions before interventions and then a month later and six months after appropriate intervention to discuss the possibility of use of this marker as predictive of progression of disease in those patients. Reslts: We demonstrated in this study that CK19 levels were significantly higher in patients with ablated focal lesions than in non ablated 1 and 6 months after intervention. Conclusion: Serum CK19 levels could be a simple, noninvasive way to predict tumor progression and evaluating treatment response and prognosis in patients with HCC amenable for intervention
530			_aIssued also as CD
653		4	_aChronic HCV
653		4	_aCK19
653		4	_aHepatocellular carcinoma
700	0		_aHanan Abdelhafez Hamed , _eSupervisor
700	0		_aMaissa Elsaid Elraziky , _eSupervisor
700	0		_aSahar Abdelaty Sharaf , _eSupervisor
905			_aNazla _eRevisor
905			_aSamia _eCataloger
942			_2ddc _cTH
999			_c63907 _d63907